August 28, 2018
Emergent BioSolutions to Acquire ADAPT Pharma®...
August 15, 2018
ADAPT Pharma & the Independent Pharmacy Cooperative (IPC) Announce Collaboration to Educate Member Pharmacies...
May 29, 2018
ADAPT Pharma® Launches NARCANDirect.com...
May 9, 2018
Quebec Government makes NARCAN™ Nasal Spray free to anyone 14 years or older through Free naloxone program...
April 30, 2018
A Retrospective Analysis & Literature Review Published in Pain Management on the Pharmacokinetic Properties of Naloxone Approved for Community Use Highlights Bioequivalence of Dose & Usability...
April 26, 2018
Adapt Pharma® donates 20,000 doses of NARCAN® (naloxone HCl) Nasal Spray to the National Council for Behavioral Health and its Residential Treatment Member Organizations....
April 25, 2018
A Retrospective Literature Review Published in Pain Management on Prescribing Naloxone for Opioid Overdose Intervention Highlights Opportunities to Expand Community Access to Help Reduce Fatalities...
April 9, 2018
Adapt Pharma® Welcomes Canadian & Ontario Governments Programs Providing NARCAN™ (naloxone HCl) Nasal Spray Free of Charge to NIHB Clients and All Ontarians through Pharmacies...
April 5, 2018
ADAPT Pharma® Welcomes Surgeon General Naloxone Advisory Strengthens Partnerships to Expand NARCAN® (naloxone HCl) Nasal Spray Affordable Access and Awareness...
March 19, 2018
ADAPT Pharma® Expands Program Offering Free NARCAN® (naloxone HCl) Nasal Spray to Eligible Schools and Universities ...
March 7, 2018
Ontario Government takes significant action to address opioid crisis; NARCAN™ Nasal Spray to be made available to all Ontarians free of charge through pharmacies...
March 5, 2018
Adapt Pharma Expands Technical and R&D Teams...
November 14, 2017
Wisconsin Attorney General & University of Wisconsin System Partner with Adapt Pharma® to Increase Access to NARCAN® (naloxone HCl) Nasal Spray...
November 3, 2017
Adapt Pharma® Presents Human Factors Study Data on Usability of NARCAN® (naloxone HCl) Nasal Spray at the 41st Association for Medical Education & Research in Substance Abus...
October 17, 2017
Adapt Pharma® Launches Roll Call Training Video to Educate Law Enforcement on NARCAN® (naloxone HCI) Nasal Spray 4mg...
October 3, 2017
Adapt Pharma® Announces Partnership with New York to Provide NARCAN® (naloxone HCI) Nasal Spray 4mg...
July 5, 2017
Opioid Overdose Antidote NARCAN™ Nasal Spray Now Carried by Nearly 400 Organizations across Canada...
June 20, 2017
Adapt Pharma Acknowledges the U.S. Drug Enforcement Administration (DEA) New Guidance to First Responders on the Hazards of Exposure to Fentanyl...
June 12, 2017
Adapt Pharma Presents Human Factors Study Data at 2017 International Conference on Opioids....
June 6, 2017
Survey Data Published on Community Use of NARCAN® (naloxone HCI) Nasal Spray 4 mg to Help Reverse Opioid-Related Overdose - Current Medical Research and Opinion Journal...
June 6, 2017
Adapt Pharma Clarifies Confusion Between NARCAN™ Nasal Spray and Injectable Naloxone Emergency Opioid Treatments...
April 24, 2017
Emergency opioid treatment NARCAN™ Nasal Spray added to NIHB Program in Canada Registered First Nations and recognized Inuit now have access to additional naloxone treatment...
April 10, 2017
Adapt Pharma Expands Free NARCAN® Nasal Spray Program to U.S. Colleges and Universities...
March 16, 2017
New Data Presented on Adapt Pharma’s Community Use of Narcan® Nasal Spray 4 mg to Reverse Opioid-Related Overdose...
February 28, 2017
Adapt Pharma Marks One-Year Anniversary of NARCAN® Nasal Spray (naloxone HCl) 4mg Launch in the U.S....
February 21, 2017
Adapt Pharma Announces European Marketing Application Filed For Naloxone Hydrochloride Nasal Spray...
January 25, 2017
NARCAN® (naloxone HCl) Nasal Spray 2mg Approved by U.S. Food and Drug Administration (FDA)...
December 1, 2016
Adapt Pharma Partners with OH Attorney General DeWine to Guarantee Public Interest Price...
November 22, 2016
Adapt Pharma Welcomes U.S. Food and Drug Administration Consumer Update Regarding Opioids...
November 4, 2016
Reported shortage of non-FDA approved improvised nasal naloxone kits....
October 6, 2016
FDA Joint Meeting Endorses Commitment to Higher Doses and Broader Access for Naloxone to Help in Fight Against Opioid Overdose ...
October 5, 2016
Adapt Pharma Announces NARCAN® coverage with California’s Medi-Cal Program. Agreement Results in Restriction-Free, $0 Copay Access to NARCAN® Nasal Spray for Millions of Californians...
October 3, 2016
Health Canada Approves Adapt Pharma’s Naloxone Hydrochloride Nasal Spray to Treat Opioid Overdose...
September 20, 2016
Newly Published Study Finds NARCAN® Nasal Spray’s Concentrated Formulation Rapidly Delivers an Effective Naloxone Dose and is Readily Usable by the General Public...
July 12, 2016
Adapt Pharma to Launch Program to Raise Awareness, Expand Access and Facilitate Product Experience of NARCAN® (Naloxone HCl) Nasal Spray - a new Treatment for Opioid Overdose...
July 6, 2016
Canada to Make Available U.S. FDA-Approved Intranasal Naloxone Medication...
May 2, 2016
Adapt Pharma submits NDS to Health Canada for Naloxone Nasal Spray...
April 28, 2016
Adapt Pharma Teams with Smith Medical Partners to Support Distribution of Free NARCAN® (Naloxone HCl) Nasal Spray Offer to All U.S. High Schools...
April 14, 2016
Introducing the NARCAN® Now App, a smartphone application providing opioid overdose recognition education and treatment instructions...
April 11, 2016
Adapt Pharma Names Mike Kelly President of U.S. Operations. Contributing Over 25 Years of Pharmaceutical Expertise to Adapt Executive Team...
February 25, 2016
NARCAN® (Naloxone Hydrochloride) NASAL SPRAY Now Available in the United States for Emergency Treatment of Known or Suspected Opioid Overdose...
January 25, 2016
Adapt Pharma to offer all U.S. high schools a free NARCAN® Nasal Spray...
January 14, 2016
Adapt Pharma facilitates NARCAN® (naloxone hydrochloride) Nasal Spray access to state and local public entities...
November 19, 2015
NARCAN® (naloxone hydrochloride) Nasal Spray approved by U.S. food and drug administration...
September 24, 2015
FDA accepts for review Adapt Pharma’s NARCAN® (naloxone hydrochloride) Nasal Spray NDA...
July 27, 2015
Adapt Pharma submits NDA to FDA for NARCAN® (Naloxone) Nasal Spray...
July 2, 2015
Adapt Pharma acquires NARCAN NDA and obtains license to the NARCAN® trademark...
June 3, 2015
Adapt Pharma Commences Rolling NDA Submission to the FDA for Intranasal Naloxone...
April 22, 2015
Adapt Pharma Announces Successful Completion of Intranasal Naloxone Study...
February 17, 2015
Adapt Pharma Announces Fast Track Designation From FDA for Naloxone Nasal Spray...
January 5, 2015
Adapt Pharma and Profector Life Sciences Enter a Development and Investment Collaboration...
December 16, 2014
Adapt Pharma Announces License Agreement for Naloxone Nasal Spray With Lightlake Therapeutics Inc....
May 2, 2014
Adapt Pharma Completes $95 Million Equity Financing U.S. Focused Specialty Pharmaceutical Company...